On May 2, 2019, a jury sitting in the District of Massachusetts
convicted five senior executives of Insys Therapeutics, Inc.
(Insys) with racketeering conspiracy in violation of Title 18,
United States Code, Section 1962(d). Among other things, the
evidence at trial demonstrated that the Insys executives operated
an elaborate scheme to bribe physicians to write prescriptions for
the drug Subsys, a fentanyl spray, in greater numbers and at higher
dosages. The bribes took the form of sham speaker programs that
purportedly paid physicians for peer-to-peer education programs but
in fact were simply payments to physicians to write more
prescriptions of Subsys. In convicting the defendants, the jury
found that they conspired to violate predicate statutes, including
the Controlled Substances Act (CSA), honest services fraud, mail
fraud and wire fraud. CSA charges are typically brought against
drug dealers; the Insys convictions were the first CSA convictions
of pharmaceutical